# Research Peptide FAQ — Ipamorelin, PT-141, Semaglutide, Tirzepatide — Peptide Biologicals > Frequently asked questions about four Research Peptide Fundamentals research peptides — ipamorelin, PT-141, semaglutide, and tirzepatide — answered plainly from the published literature, with citations and evidence-quality flags. Direct, citation-anchored answers that name evidence quality as plainly as they name the finding itself. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates GHS-R1a, the ghrelin receptor, on growth-hormone-releasing cells in the pituitary gland. Its founding 1998 characterization showed it releases growth hormone potently in animal and cell models without meaningfully raising cortisol or prolactin, even at doses far above its effective dose [6], the selectivity that distinguishes it from older growth-hormone-releasing peptides. It has never been approved as a drug for any indication, and its only placebo-controlled human trial, in patients recovering from bowel surgery, did not meet its primary endpoint [3]. ## What are the risks of ipamorelin? The honest answer is that most of ipamorelin's risk profile is inferred from mechanism and animal data rather than from confirmed human outcomes, because only one small human trial exists and it did not demonstrate efficacy [3]. Mechanistically, growth-hormone-axis stimulation raises theoretical concerns around active malignancy and glucose regulation, since GH is a counter-regulatory hormone [6]. A 28-day rat study of a related, but different, ghrelin-receptor agonist found dose-dependent heart-muscle damage, a same-class signal rather than an ipamorelin-specific finding, but one this desk treats as relevant to anyone with existing cardiovascular disease [2]. Beyond that, no chronic human safety database exists, and research-grade material sold outside a clinical trial carries no verified purity or identity. ## What is PT-141 approved for? PT-141, known clinically as bremelanotide, is FDA-approved for exactly one indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women, based on two Phase 3 trials showing significant improvement in desire and reduced desire-related distress over 24 weeks [10], with sustained benefit and no new safety signals in a 52-week open-label extension [11]. It is not approved for men, for postmenopausal women, or for general sexual-performance enhancement, uses that account for much of its research-community reputation but sit outside the population and endpoints the pivotal trials actually tested [10][12]. ## What does the PT-141 peptide do? PT-141 activates melanocortin receptors, chiefly MC4R, concentrated in hypothalamic and limbic brain regions involved in sexual motivation. A randomized fMRI study found that this receptor agonism increased sexual desire for up to 24 hours and altered brain activity in response to erotic stimuli in women with hypoactive sexual desire disorder [9]. That is a central, brain-level mechanism, distinct from small-molecule erectile-dysfunction drugs, which act peripherally on blood vessels. A 2025 animal study specifically found that bremelanotide did not change reward-circuit gene expression or enhance the rewarding aspect of sexual interaction, a useful check against overstating the mechanism [8]. ## What is semaglutide used for? Semaglutide is FDA-approved for type 2 diabetes, chronic weight management, reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, since 2025, a liver condition called MASH. The evidence behind these approvals is substantial: a 17,604-person cardiovascular-outcomes trial found a 20% relative reduction in major adverse cardiovascular events [15], and a dedicated weight-management trial found -14.9% mean body weight at 68 weeks versus -2.4% with placebo [16]. It is not, however, the strongest performer in its own drug class, as the next answer explains. ## How does semaglutide work for weight loss? Semaglutide's weight effect is largely central rather than metabolic: the peptide reaches hypothalamic and brainstem circuits that regulate hunger, activating fullness-signaling neurons and suppressing hunger-signaling ones, while also slowing stomach emptying to prolong the sensation of fullness. In the pivotal weight-management trial, that combination produced a mean -14.9% body-weight change at 68 weeks versus -2.4% with placebo [16]. In the one trial that measured semaglutide against tirzepatide directly, however, tirzepatide produced significantly greater weight loss, -20.2% versus -13.7% [13], a result this desk treats as more informative than either trial read in isolation. ## What is tirzepatide? Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP and GLP-1 receptors, the first approved dual incretin agonist. It is FDA-approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea [18]. In the one trial that directly compared it against semaglutide, tirzepatide produced significantly greater weight loss, -20.2% versus -13.7% (P<0.001) [13], the strongest single head-to-head result of any comparison covered on this desk. ## What does tirzepatide do in the body? By engaging both GIP and GLP-1 receptors, tirzepatide increases glucose-dependent insulin release, suppresses glucagon, and slows gastric emptying, the combination behind both its glycemic and weight effects. In a 2,539-person trial, the highest studied dose produced -20.9% mean body-weight change at 72 weeks versus -3.1% with placebo [20]. Exactly how much of tirzepatide's advantage over single-receptor agonists comes specifically from the added GIP receptor activation, versus other pharmacokinetic differences, remains an open mechanistic question rather than a fully resolved one [18]. ## Which of these four peptides has the strongest evidence? By trial count, participant numbers, and outcome breadth, semaglutide and tirzepatide have the strongest evidence on this desk, each backed by multiple large randomized trials across thousands of participants [13][14][15][16][18][20][21]. Between the two, tirzepatide has the single most direct comparative result available anywhere on this desk: a statistically significant head-to-head weight-loss win over semaglutide [13]. PT-141 has genuinely solid Phase 3 evidence, but only for one narrow indication [10][11]. Ipamorelin has the thinnest human record of the four: one small trial, and it did not meet its primary endpoint [3]. ## Are peptides regulated and studied the same way as small-molecule drugs? Not exactly. Peptides are larger, more fragile molecules than typical small-molecule drugs, and most cannot survive digestion intact, which is why the majority of compounds on this desk are injected rather than taken as pills. That fragility also shapes how they are engineered: unnatural amino acids, D-amino acid substitutions, cyclic structures, and fatty-acid side chains are all common ways of extending a peptide's working life in the body, tricks a conventional small molecule rarely needs. Regulatory review itself follows the same FDA pathways regardless of molecule type, but a peptide's manufacturing, purity verification, and immunogenicity testing tend to be more involved than for a small molecule. ## Is ipamorelin FDA-approved? No. Ipamorelin has never been approved by the FDA or any other regulator for any indication. It has been formally investigated once, for postoperative gut recovery after bowel surgery, and that trial missed its primary endpoint [3]. It is marketed exclusively as a research chemical, and in 2024 the FDA removed ipamorelin acetate from the interim list of substances eligible for compounding-pharmacy use, a regulatory tightening rather than a loosening of its status. ## Why are most research peptides injected instead of taken as pills? Peptides are chains of amino acids held together by the same kind of bond that digestive enzymes are specifically built to break. An ordinary peptide swallowed as a pill would be broken down in the stomach and intestine before it could reach the bloodstream intact. Semaglutide is the one exception on this desk: its oral tablet formulation adds an absorption enhancer that briefly changes stomach-lining chemistry, but even then oral bioavailability stays below 1%, and the tablet must be taken strictly fasted to work at all. That fragility, not marketing preference, is why injections dominate this class. --- An evidence-grade digest: what is cited stays cited, what is not established is called unestablished, and nothing here is a recommendation.